Moxifloxacin in the Treatment of Elderly Patients with Community-Acquired Pneumonia
Abstract
Elderly patients are at increased risk of developing lower respiratory tract infections compared with younger age groups. A wide spectrum of pathogens may be involved, depending on the patient’s underlying comorbidities and environmental exposure.Streptococcus pneumoniae remains the most common bacterial isolate in community-acquired pneumonia, followed by Haemophilus influenzae, Moraxella catarrhalis and atypical organisms such as Chlamydia pneumoniae, Legionella spp. and Mycoplasma pneumoniae. International guidelines have included the use of the new generation of fluoroquinolones as monotherapy in elderly patients with community-acquired pneumonia. Moxifloxacin is a synthetic fluoroquinolone with a broad spectrum of antimicrobial activity that is approved for use in the treatment of lower respiratory tract infections. Itsin vitro activity is impacted less by mutations in S. pneumoniae than other fluoroquinolones. It has pharmacological characteristics that support once-daily dosing regimens and early conversion from intravenous to oral therapy, allowing for an early hospital discharge and subsequent cost reduction. The drug has an excellent safety profile. Gastrointestinal manifestations are among the most commonly reported adverse events. Moxifloxacin does not appear to have an increased risk of malignant cardiac arrhythmias, but caution is recommended in elderly patients with uncorrected hypokalemia or hypomagnesemia, or those receiving class IA or III antiarrhythmic…
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.